Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma
- 1 November 2014
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 66 (5) , 929-935
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (R01CA134466-4)
- National Institutes of Health
This publication has 20 references indexed in Scilit:
- Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancerJournal of Translational Medicine, 2013
- Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend AnalysisEuropean Urology, 2011
- Development and evaluation of BioScoreCancer, 2009
- DNA topoisomerase II and its growing repertoire of biological functionsNature Reviews Cancer, 2009
- The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothingNucleic Acids Research, 2008
- RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPYJournal of Urology, 2005
- Innovations and Challenges in Renal CancerClinical Cancer Research, 2004
- An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign ScoreJournal of Urology, 2002
- Functional and Regulatory Characteristics of Eukaryotic Type II DNA TopoisomeraseCritical Reviews in Biochemistry and Molecular Biology, 2001
- Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome VariablesLaboratory Investigation, 2000